vs
Enovis CORP（ENOV）与Inogen Inc（INGN）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是Inogen Inc的8.0倍（$548.9M vs $68.6M）。Inogen Inc同比增速更快（3.4% vs -2.2%）。Enovis CORP自由现金流更多（$29.1M vs $-1.9M）。过去两年Enovis CORP的营收复合增速更高（9.8% vs 4.2%）
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
Inogen Inc是一家专注于呼吸医疗设备领域的医疗科技企业，主要研发、生产和销售便携式制氧机及配套呼吸护理产品，面向北美、欧洲等地区需要长期氧疗的慢性呼吸系统疾病患者，服务居家及出行场景，提升用户生活质量。
ENOV vs INGN — 直观对比
营收规模更大
ENOV
是对方的8.0倍
$68.6M
营收增速更快
INGN
高出5.6%
-2.2%
自由现金流更多
ENOV
多$31.0M
$-1.9M
两年增速更快
ENOV
近两年复合增速
4.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $548.9M | $68.6M |
| 净利润 | $-571.1M | — |
| 毛利率 | 59.9% | 51.4% |
| 营业利润率 | -101.7% | -13.6% |
| 净利率 | -104.1% | — |
| 营收同比 | -2.2% | 3.4% |
| 净利润同比 | 18.8% | — |
| 每股收益（稀释后） | $-9.99 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENOVINGN
| Q4 25 | $548.9M | $68.6M | ||
| Q3 25 | $564.5M | $79.1M | ||
| Q2 25 | $558.8M | $79.2M | ||
| Q1 25 | — | $68.5M | ||
| Q4 24 | $561.0M | $66.3M | ||
| Q3 24 | $505.2M | $74.9M | ||
| Q2 24 | $525.2M | $74.4M | ||
| Q1 24 | $516.3M | $63.1M |
净利润ENOVINGN
| Q4 25 | $-571.1M | — | ||
| Q3 25 | $-36.7M | $-5.3M | ||
| Q2 25 | $-56.0M | $-4.2M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | $-703.2M | — | ||
| Q3 24 | $-31.5M | $-6.0M | ||
| Q2 24 | $-18.6M | $-5.6M | ||
| Q1 24 | $-72.0M | $-14.6M |
毛利率ENOVINGN
| Q4 25 | 59.9% | 51.4% | ||
| Q3 25 | 59.3% | 52.2% | ||
| Q2 25 | 59.5% | 52.2% | ||
| Q1 25 | — | 53.1% | ||
| Q4 24 | 54.8% | 54.7% | ||
| Q3 24 | 56.7% | 55.2% | ||
| Q2 24 | 55.0% | 57.4% | ||
| Q1 24 | 57.7% | 54.5% |
营业利润率ENOVINGN
| Q4 25 | -101.7% | -13.6% | ||
| Q3 25 | -3.0% | -9.0% | ||
| Q2 25 | -8.4% | -7.7% | ||
| Q1 25 | — | -11.2% | ||
| Q4 24 | -118.5% | -17.2% | ||
| Q3 24 | -6.3% | -10.4% | ||
| Q2 24 | -8.4% | -9.5% | ||
| Q1 24 | -6.8% | -25.8% |
净利率ENOVINGN
| Q4 25 | -104.1% | — | ||
| Q3 25 | -6.5% | -6.7% | ||
| Q2 25 | -10.0% | -5.2% | ||
| Q1 25 | — | -9.0% | ||
| Q4 24 | -125.4% | — | ||
| Q3 24 | -6.2% | -8.0% | ||
| Q2 24 | -3.5% | -7.5% | ||
| Q1 24 | -13.9% | -23.1% |
每股收益（稀释后）ENOVINGN
| Q4 25 | $-9.99 | $-0.26 | ||
| Q3 25 | $-0.64 | $-0.20 | ||
| Q2 25 | $-0.98 | $-0.15 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | $-12.69 | $-0.41 | ||
| Q3 24 | $-0.58 | $-0.25 | ||
| Q2 24 | $-0.34 | $-0.24 | ||
| Q1 24 | $-1.32 | $-0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.6M | $103.7M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $192.2M |
| 总资产 | $4.4B | $298.6M |
| 负债/权益比越低杠杆越低 | 0.67× | — |
8季度趋势，按日历期对齐
现金及短期投资ENOVINGN
| Q4 25 | $33.6M | $103.7M | ||
| Q3 25 | $44.1M | $106.5M | ||
| Q2 25 | $38.5M | $103.7M | ||
| Q1 25 | — | $118.9M | ||
| Q4 24 | $48.2M | $113.8M | ||
| Q3 24 | $35.4M | $105.7M | ||
| Q2 24 | $35.0M | $97.9M | ||
| Q1 24 | $66.3M | $107.4M |
总债务ENOVINGN
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ENOVINGN
| Q4 25 | $2.0B | $192.2M | ||
| Q3 25 | $2.6B | $197.2M | ||
| Q2 25 | $2.6B | $199.5M | ||
| Q1 25 | — | $198.0M | ||
| Q4 24 | $2.6B | $173.9M | ||
| Q3 24 | $3.3B | $185.4M | ||
| Q2 24 | $3.3B | $187.6M | ||
| Q1 24 | $3.3B | $191.9M |
总资产ENOVINGN
| Q4 25 | $4.4B | $298.6M | ||
| Q3 25 | $5.0B | $307.0M | ||
| Q2 25 | $4.9B | $312.0M | ||
| Q1 25 | — | $308.4M | ||
| Q4 24 | $4.7B | $296.2M | ||
| Q3 24 | $5.6B | $306.2M | ||
| Q2 24 | $5.4B | $308.9M | ||
| Q1 24 | $5.5B | $315.6M |
负债/权益比ENOVINGN
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.6M | $-943.0K |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-1.9M |
| 自由现金流率自由现金流/营收 | 5.3% | -2.8% |
| 资本支出强度资本支出/营收 | 9.7% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $22.8M | $-13.7M |
8季度趋势，按日历期对齐
经营现金流ENOVINGN
| Q4 25 | $82.6M | $-943.0K | ||
| Q3 25 | $47.8M | $2.2M | ||
| Q2 25 | $-1.6M | $4.3M | ||
| Q1 25 | — | $-16.8M | ||
| Q4 24 | $88.3M | $-3.0M | ||
| Q3 24 | $53.6M | $7.0M | ||
| Q2 24 | $7.8M | $6.7M | ||
| Q1 24 | $-36.2M | $-4.7M |
自由现金流ENOVINGN
| Q4 25 | $29.1M | $-1.9M | ||
| Q3 25 | $3.4M | $1.6M | ||
| Q2 25 | $-44.9M | $3.7M | ||
| Q1 25 | — | $-17.1M | ||
| Q4 24 | $35.1M | $-3.3M | ||
| Q3 24 | $2.4M | $5.3M | ||
| Q2 24 | $-31.6M | $6.6M | ||
| Q1 24 | $-73.1M | $-6.1M |
自由现金流率ENOVINGN
| Q4 25 | 5.3% | -2.8% | ||
| Q3 25 | 0.6% | 2.0% | ||
| Q2 25 | -8.0% | 4.6% | ||
| Q1 25 | — | -24.9% | ||
| Q4 24 | 6.3% | -5.0% | ||
| Q3 24 | 0.5% | 7.1% | ||
| Q2 24 | -6.0% | 8.9% | ||
| Q1 24 | -14.2% | -9.6% |
资本支出强度ENOVINGN
| Q4 25 | 9.7% | 1.4% | ||
| Q3 25 | 7.9% | 0.7% | ||
| Q2 25 | 7.7% | 0.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | 9.5% | 0.5% | ||
| Q3 24 | 10.1% | 2.2% | ||
| Q2 24 | 7.5% | 0.1% | ||
| Q1 24 | 7.2% | 2.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
INGN
暂无分部数据
